There are currently 428 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
3D Printed Breast Models in the Surgical Management of Breast Cancer
NCT05755984
Recruiting
To learn if providing a 3-D printed model of the breast can help breast cancer patients make decisions related to their care. During this study, some study participants will receive the 3-D printed model and some study participants will receive traditional breast imaging scans to learn if the 3-D printed model
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
NCT03643861
Recruiting
This study offers 5 fractions of radiation treatment through partial breast irradiation in patients with early stage breast cancer after having a lumpectomy.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/06/2025
Locations: University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham, Alabama
Conditions: Breast Cancer
Register for Updates
Resistance Training and Post Workout Protein to Improve Body Composition During Neoadjuvant Chemotherapy for Breast Cancer
NCT06858449
Recruiting
In this study, the investigators hypothesize that a high dose of post-workout protein nutrition regimen focused on food quality and an observed exercise regimen utilizing high-load resistance training initiated during or after cancer treatment will improve body composition and functional capacity.
Gender:
FEMALE
Ages:
Between 20 years and 89 years
Trial Updated:
03/05/2025
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Cancer, Breast Cancer
Register for Updates
CTNNA1 Familial Expansion Study
NCT05126290
Recruiting
The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cancer Gene Mutation, Gastric Cancer, Breast Cancer
Register for Updates
Susan G. Komen's ShareForCures
NCT05654246
Recruiting
ShareForCures (SFC) is a community-based participatory research registry, and its prime objective is to engage participants representative of the United States breast cancer patient population -including minoritized and historically marginalized people, persons, or communities-to ensure the data researchers use to study breast cancer is as diverse as the people touched by this disease. In doing so, researchers will have a better understanding of breast cancer, and everyone can potentially benefi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Susan G. Komen, Dallas, Texas
Conditions: Breast Cancer
Register for Updates
F-Tryptophan PET/CT in Human Cancers
NCT05556473
Recruiting
Imaging procedures such as 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Intracranial Glioma, Metastatic Brain Tumor, Breast Cancer, Neuroendocrine Tumors, Rectal Cancer
Register for Updates
VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT05608252
Recruiting
This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations
Conditions: Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Register for Updates
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT05020860
Recruiting
The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving chemotherapy prior to surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Harris Health System - Smith Clinic, Houston, Texas +1 locations
Conditions: Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
Register for Updates
The COMPASSION Study
NCT06507930
Recruiting
The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Breast Carcinoma
Register for Updates
Prospective Evaluation of Targeted Axillary Dissection (TAD)
NCT04998682
Recruiting
The purpose of this research is to evaluate how to manage the axillary lymph nodes in patients with breast cancer. The investigators will determine if a sampling of the lymph nodes under the arm will give the information necessary to determine if fewer lymph nodes can be removed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: University of Miami, Miami, Florida
Conditions: Breast Cancer
Register for Updates
Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT04886531
Recruiting
Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed prior to Day 1 of week 4 of treatment. Following surgery, patients will receive standard of care HER2-directed and endocrine therapy at the treating physician's discretion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: University of Illinois Cancer Center, Chicago, Illinois +3 locations
Conditions: Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Register for Updates
Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study
NCT04371913
Recruiting
The goal of the study is to investigate the feasibility of enabling a second chance for breast conservation in patients with in-breast recurrences after a previous lumpectomy and RT, investigators propose to test partial breast irradiation with the target volume encompassing the entire surgical bed with 1.0-1.5 cm margins.
Gender:
FEMALE
Ages:
Between 19 years and 90 years
Trial Updated:
02/18/2025
Locations: New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York +2 locations
Conditions: Breast Cancer
Register for Updates